Biohaven Ltd
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures Power of Attorney (contained on signature page hereto)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| BIOHAVEN LTD. | |
| Dated: February 29, 2024 | |
|---|---|
| By: | /s/ VLAD CORIC, M.D. |
| Vlad Coric, M.D. | |
| Chief Executive Officer | |
| (On behalf of the Registrant and as the Principal Executive Officer) | |
| By: | /s/ MATTHEW BUTEN |
| Matthew Buten | |
| Chief Financial Officer | |
| (Principal Financial Officer) | |
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Vlad Coric as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this Annual Report on Form 10-K of Biohaven Ltd., and any or all amendments thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ VLAD CORIC, M.D. | Chief Executive Officer and Director(Principal Executive Officer) | February 29, 2024 |
| Vlad Coric, M.D. | ||
| /s/ MATTHEW BUTEN | Chief Financial Officer (Principal Financial Officer) | February 29, 2024 |
| Matthew Buten | ||
| /s/ GEORGE C. CLARK | Chief Accounting Officer(Principal Accounting Officer) | February 29, 2024 |
| George C. Clark | ||
| /s/ GREGORY H. BAILEY, M.D. | Director | February 29, 2024 |
| Gregory H. Bailey, M.D. | ||
| /s/ JOHN W. CHILDS | Director | February 29, 2024 |
| John W. Childs | ||
| /s/ JULIA P. GREGORY | Director | February 29, 2024 |
| Julia P. Gregory | ||
| /s/ MICHAEL HEFFERNAN | Director | February 29, 2024 |
| Michael Heffernan | ||
| /s/ ROBERT J. HUGIN | Director | February 29, 2024 |
| Robert J. Hugin | ||
| /s/ KISHEN MEHTA | Director | February 29, 2024 |
| Kishen Mehta | ||
| /s/ IRINA ANTONIJEVIC | Director | February 29, 2024 |
| Irina Antonijevic | ||
Biohaven Ltd.
Financial Statements
For the Years Ended December 31, 2023, 2022 and 2021
| Page | |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) | 2 |
| Consolidated Balance Sheets | 4 |
| Consolidated Statements of Operations | 5 |
| Consolidated Statements of Comprehensive Loss | 6 |
| Consolidated Statements of Shareholders' Equity | 7 |
| Consolidated Statements of Cash Flows | 8 |
| Notes to Consolidated Financial Statements | 9 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.